Comparative Pharmacology
Head-to-head clinical analysis: ANTIZOL versus VALNAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTIZOL versus VALNAC.
ANTIZOL vs VALNAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antizol (fomepizole) is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the oxidation of ethanol to acetaldehyde. It also inhibits the metabolism of ethylene glycol and methanol to their toxic metabolites.
Valproate semisodium (valproic acid derivative) increases GABA levels in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, and modulates voltage-gated sodium channels and T-type calcium channels. The combination (valproate semisodium) dissociates in the gastrointestinal tract to valproic acid and sodium valproate, providing rapid absorption and sustained release.
Initial: 15 mg/kg IV over 10 minutes, then 3 mg/kg IV every 4 hours for 2 doses, then 3 mg/kg IV every 6 hours for 4 doses.
Adults: 650 mg orally twice daily, with a maximum of 1300 mg per day.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours in adults. Clinical context: Dose adjustment recommended in severe renal impairment (CrCl <30 mL/min) due to prolonged half-life.
3-5 hours (healthy adults). In severe renal impairment (CrCl <30 mL/min), half-life extends to 12-24 hours, increasing risk of accumulation and toxicity.
Renal: 80-95% as parent drug and metabolites. Fecal: <5%. Biliary excretion is negligible.
Primarily renal (90% unchanged drug), with 10% biliary-fecal. In renal impairment, half-life prolongs significantly, requiring dose adjustment.
Category C
Category C
Antidote
Antidote